SpliceBio

SpliceBio takes over Times Square! 🗽 Proud to see our $135M Series B milestone spotlighted on the iconic @Nasdaq Tower. Huge thanks to our team & investors powering the next wave of genetic medicines! 💡

Our work in genetic medicines is guided by shared values and scientific excellence. We’re grateful to the women at SpliceBio and to those everywhere whose work helps translate discovery into transformative therapies for patients.

We’re ready for an active week ahead engaging with the #biotech community! Logistics below. We look forward to sharing our progress and connecting with partners.

For #RareDiseaseDay, we came together to name our newest plush teammate, “Tira,” inspired by a zebra in Kenya born with a rare genetic condition that altered her stripe pattern.🦓Tira is a reminder of why we do this work and who we do it for.

More #WomeninSTEM below!

We have a fierce appreciation for women in STEM! On International Day of Women and Girls in Science, we recognize all of the incredible women at SpliceBio who are transforming the future of genetic medicines and are paving the way for future generations. #WomeninSTEM

Listen to the full episode on The BioHub Podcast.⬇️ Spotify: lnkd.in/e-6YHEBk Apple: lnkd.in/eyt85Zpx

#Stargardt disease is a condition that leads to central vision loss & blindness. Caused by biallelic mutations in the ABCA4 gene, it remains a significant unmet need with no approved treatments. This #LowVisionAwarenessMonth, learn how SB-007 targets the underlying genetic cause.

Details: splice.bio/splicebio-init…

We are pleased to announce that the first patient has been dosed in the Part B dose expansion portion of our Phase 1/2 ASTRA clinical trial of SB-007, a dual adeno-associated viral vector gene therapy for the treatment of #Stargardt disease.

Read here: businesswire.com/news/home/2026…

We're thrilled to welcome Don Munoz to SpliceBio as our CFO. With deep financial expertise and broad experience within the life sciences industry, Don will be instrumental as we enter our next stages of development and position SpliceBio for long-term value creation.

San Francisco, here we come! Next week, the SpliceBio team will join industry colleagues at the J.P. Morgan Healthcare Conference. We’re looking forward to meaningful conversations and new connections at #JPM26.

We’re proud of the milestones and culture we built together in 2025. From musical bingo to closing our Series B financing, plus an ugly sweater contest & kudos shared across the team, it was a year of connection & progress. Wishing everyone a joyful holiday season from SpliceBio.

Tune in: open.spotify.com/episode/67KLjt…

At Jefferies 2025, CEO Miquel joined The BioHub Podcast to share the story behind SpliceBio, our protein splicing platform and the progress of our lead program, SB-007 for Stargardt disease, being investigated in our Phase 1/2 study.

Thrilled to win 'Series B Raise of the Year' at #LifestarAwards 2025! This award recognizes our record-breaking $135M Series B, the largest biotech raise in Spain to date. Grateful to our investors & team for their commitment to advancing the next wave of #geneticmedicines.

CEO Miquel Vila-Perello, CBO Gerard Caelles and CMO Aniz Girach look forward to connecting in London to discuss our #genetherapy approach for #stargardtdisease as well as our pipeline in ophthalmology and neurology. See you at #Jefferies2025!

Our co-founder and CEO traveled to Vienna this week to participate in a dynamic panel of strategic advisors discussing our pivotal $135M Series B financing. Great conversation, amazing energy and a big thank you to everyone at #BioEurope2025!

CEO, Miquel Vila-Perello, will join a panel of strategic investors who played a key role in our pivotal $135M Series B financing at #BIOEurope in 📍Vienna, Austria. Learn more: #business-of-biotech_sipping-on-success-splicebios-series-b-and-the-revival-of-gene-therapy_15-30" target="_blank" rel="nofollow noopener">informaconnect.com/bioeurope/agen…

We're a finalist for the 2025 European #LifestarAwards in two categories: ‘Biotech of the Year’ & ‘Best Series B Raise!’ This honor underscores our mission to develop the next-gen of #genetherapies & inspires us to keep pushing the boundaries of what’s possible for patients.